Immunoconjugates Archives

GSK Submits Multiple Myeloma Drug to Regulators

B-cell maturation antigen (BCMA), Biologics License Application (BLA), Blockbusters, Blood Cancers, FDA, FDA/Regulatory, Health Technology, Immunoconjugates, Monoclonal Antibodies, Multiple Myeloma, Overall Response Rate (ORR)

GlaxoSmithKline submitted a Biologics License Application to the U.S. FDA based upon results from the pivotal DREAMM-2 Phase III trial of belantamab mafodotin in multiple myeloma.

December 17, 2019/by BioSpace

FDA Lifts Partial Clinical Hold for Mersana’s XMT-1522

Biopharma, Breast Cancer, Clinical Hold, Clinical Trials, FDA/Regulatory, Gastric Cancer, Immunoconjugates, Non-Small Cell Lung Cancer, Ovarian Cancer, Tumors

Mersana Therapeutics Inc. announced that the U.S. Food and Drug Administration lifted the partial clinical hold on the Phase 1 study of the experimental cancer drug XMT-1522.

September 17, 2018/by GlobeNewswire